Polyneuropathy is inadequately treated despite increasing symptom intensity in individuals with and without diabetes (PROTECT follow‐up study)
| العنوان: | Polyneuropathy is inadequately treated despite increasing symptom intensity in individuals with and without diabetes (PROTECT follow‐up study) |
|---|---|
| المؤلفون: | Rüdiger Landgraf, Karlheinz Reiners, Oliver Schnell, Alexander Strom, Ralf Lobmann, Kristian Rett, Dan Ziegler |
| المصدر: | Journal of Diabetes Investigation Journal of Diabetes Investigation, Vol 11, Iss 5, Pp 1272-1277 (2020) |
| بيانات النشر: | John Wiley and Sons Inc., 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Male, medicine.medical_specialty, Gabapentin, Endocrinology, Diabetes and Metabolism, Pregabalin, 030209 endocrinology & metabolism, Type 2 diabetes, Diseases of the endocrine glands. Clinical endocrinology, 03 medical and health sciences, Polyneuropathies, 0302 clinical medicine, Pharmacotherapy, Diabetic Neuropathies, Internal medicine, Diabetes mellitus, Polyneuropathy, Internal Medicine, medicine, Humans, 030212 general & internal medicine, Symptom intensity, Aged, business.industry, Follow up studies, General Medicine, Articles, medicine.disease, RC648-665, Prognosis, Symptom Flare Up, Treatment, Clinical Science and Care, Diabetes Mellitus, Type 2, Case-Control Studies, Original Article, Female, Symptom Assessment, business, medicine.drug, Follow-Up Studies |
| الوصف: | Aims/Introduction Despite its major clinical impact, distal symmetric polyneuropathy remains frequently undiagnosed and undertreated in clinical practice. We previously reported in the PROTECT Study that 70% of type 2 diabetes patients with distal symmetric polyneuropathy were unaware of having the latter condition. Materials and Methods In the present follow up after 2.5 ± 0.7 years, 122 and 85 participants with and without type 2 diabetes, respectively, completed questionnaires to obtain information about the further course of disease and its management. Results At follow up, 49 and 48% of the respondents with type 2 diabetes and without diabetes, respectively, reported that the intensity of paresthesia or numbness in the feet increased, whereas for burning and pain in the feet the corresponding percentages were 56 and 61%. However, 33 and 40% of the respondents with type 2 diabetes and without diabetes, respectively, reporting neuropathic symptoms at follow up did not receive any pharmacotherapy. Pharmacotherapy of neuropathic symptoms at follow up among participants with type 2 diabetes and without diabetes included mainly World Health Organization Step 1 analgesics (17% each; excluding acetylsalicylic acid), pregabalin/gabapentin (20 and 12%), vitamin B complex (13 and 22%), benfotiamine (13 and 2%), opioids (7 and 12%), antidepressants (4 and 5%) and α‐lipoic acid (4 and 2%). Conclusions These findings point to insufficient care, inadequate treatment adherence or limited efficacy of treatments in patients with polyneuropathy, suggesting that effective measures should be implemented to correct these healthcare deficits. This survey shows that despite increasing intensity of neuropathic symptoms, a significant proportion of participants with and without diabetes did not receive any pharmacotherapy for these symptoms or received agents, such as World Health Organization Step 1 analgesics, which are not recommended by evidence‐based guidelines. These data suggest insufficient care, inadequate treatment adherence or limited effectiveness of treatments in patients with polyneuropathy. |
| اللغة: | English |
| تدمد: | 2040-1124 2040-1116 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc0833631fb341ff5d09c42d5209720bTest http://europepmc.org/articles/PMC7477515Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....bc0833631fb341ff5d09c42d5209720b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20401124 20401116 |
|---|